Setting 
My Cart
Toggle Nav
Close
  • Menu
  • Setting

Metformin HCl

Catalog No.
B1970
Anti-diabetic drug
Grouped product items
SizePriceStock Qty
10mM (in 1mL DMSO)
$55.00
In stock
10g
$61.00
In stock
50g
$132.00
In stock
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

Metformin hydrochloride (Metformin HCl; CAS 1115-70-4) is a widely studied small molecule employed in biomedical research primarily for investigating glucose metabolism and type 2 diabetes mechanisms. It acts through selective inhibition of hepatic gluconeogenesis without directly increasing insulin secretion. The molecular targets include activation of AMP-activated protein kinase (AMPK), subsequently suppressing acetyl-CoA carboxylase (ACC) activity, attenuating lipid biosynthesis, and promoting fatty acid oxidation. Additionally, metformin inhibits mitochondrial glycerophosphate dehydrogenase (mGPD), changing cellular redox status and reducing lactate-driven gluconeogenesis pathways. Key research applications of Metformin HCl include studies on glucose homeostasis, metabolic disorders, and AMPK signaling cascades.

References:
1. Madiraju AK, Erion DM, Rahimi Y et al.  Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase.  Nature. 2014 Jun 26;510(7506):542-6.
2. Zhou G, Myers R, Li Y et al.  Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001 Oct;108(8):1167-74.
3. Shaw RJ, Lamia KA, Vasquez D et al.  The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005 Dec 9;310(5754):1642-6.

Product Citation

Chemical Properties

Physical AppearanceA solid
StorageStore at -20°C
M.Wt165.62
Cas No.1115-70-4
FormulaC4H12ClN5
Solubilityinsoluble in EtOH; ≥30.7 mg/mL in H2O; ≥8.3 mg/mL in DMSO
Chemical Name3-(diaminomethylidene)-1,1-dimethylguanidine;hydrochloride
SDFDownload SDF
Canonical SMILESCN(C)C(=N)N=C(N)N.Cl
Shipping ConditionSmall Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips We do not recommend long-term storage for the solution, please use it up soon.

Protocol

Kinase experiment [1]:

AMPK assay

For the AMPK assay, cells were seeded in six-well plates at 1.5 × 106 cells/well in DMEM containing 100 U/ml penicillin, 100 μg/ml streptomycin, 10% FBS, 100 nM insulin, 100 nM dexamethasone, and 5 μg/ml transferrin for 4 hours. Cells were then cultured in serum-free DMEM for 16 hours followed by treatment for 1 hour or 7 hours with control medium, 5-amino-imidazole carboxamide riboside (AICAR), or metformin at concentrations indicated. For a 39-hour treatment, cells for both control and metformin (10 or 20 μM) groups were cultured in DMEM plus 5% FBS and 100 nM insulin, and the fresh control and metformin-containing medium were replaced every 12 hours (last medium change was 3 hours before harvest). After treatment, the cells were directly lysed in digitonin-containing and phosphatase inhibitor–containing buffer A , followed by precipitation with ammonium sulfate at 35% saturation. AMPK activity was determined by measurement of phosphorylation of a synthetic peptide substrate, SAMS (HMRSAMSGLHLVKRR).

Cell experiment [1]:

Cell lines

Rat primary hepatocytes

Preparation method

The solubility of this compound in DMSO is limited. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

10, 20, 500 μM, 2 mM; 39h;

Applications

Metformin activated AMPK in primary hepatocytes. Moreover, Metformin (2 mM, 3 hours) stimulated AMPK activity in skeletal muscle in association with induction of glucose uptake. Metformin (500 μM) reduced hepatic SREBP-1 expression in rat hepatocytes.

Animal experiment:

Animal models

Male C57BL/6 mice model;

Dosage form

200 mg/kg, oral gavage, twice daily for 5 days; or 250 mg/kg, intraperitoneal injection, for 3 days

Applications

Acetyl-CoA carboxylase (ACC) activity were reduced in metformin-treated rats [1]. Moreover, metformin required LKB1 in the liver to lower blood glucose levels [2].

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

1. Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., Musi, N., Hirshman, M. F., Goodyear, L. J. and Moller, D. E. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 108, 1167-1174

2. Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S. H., Bardeesy, N., Depinho, R. A., Montminy, M. and Cantley, L. C. (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 310, 1642-1646

Quality Control

Quality Control & MSDS

View current batch:

Chemical structure

Metformin HCl

Related Biological Data

Metformin HCl

Related Biological Data

Metformin HCl

Related Biological Data

Metformin HCl

Related Biological Data

Metformin HCl

Related Biological Data

Metformin HCl